A humanized afucosylated version of the EphA3 antibody IIIA4 (Ifabotuzumab/KB004) was also investigated in a clinical trial (NCT01211691) in patients with EphA3-expressing hematologic malignancies [46]. This evidence concerns the gene EPHA3 and hematologic disorder.